Hosted on MSN21m
What to Expect From Pfizer's Next Quarterly Earnings ReportValued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing ...
A federal appeals court revived a lawsuit challenging Pfizer Inc.‘s fellowship program aimed at building a diverse workforce, ...
A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...
FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback